The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Anticipated Rise In Market Value Of The Arthritis Monoclonal Antibodies Market During The Forecast Period?
The arthritis monoclonal antibodies market has demonstrated significant expansion in recent years. Its valuation is set to increase from $66.45 billion in 2025 to $71.66 billion in 2026, progressing at a compound annual growth rate (CAGR) of 7.8%. The historical growth of this market is linked to factors such as the increasing prevalence of rheumatoid arthritis, the limited effectiveness of conventional dmards, a growing awareness of biologic therapies, the expansion of hospital-based rheumatology care, and rising healthcare expenditure.
The arthritis monoclonal antibodies market is anticipated to experience robust expansion over the coming years. Its valuation is projected to reach $98.46 billion by 2030, progressing at a compound annual growth rate (CAGR) of 8.3%. This anticipated growth during the forecast period is fueled by several factors, including the advancement of next-generation monoclonal antibodies, a rise in the introduction of biosimilars, the expansion of personalized immunotherapy methods, an increasing elderly demographic suffering from arthritis, and enhanced reimbursement policies for biologics. Key developments anticipated in the forecast timeframe encompass a greater embrace of biologic treatments for autoimmune arthritis, a growing inclination towards targeted monoclonal antibody therapies, an increase in proactive and intensive treatment strategies, the wider availability of biosimilars for arthritis monoclonal antibodies, and better patient access via hospitals and specialized clinics.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3449&type=smp
Which Major Drivers Are Influencing The Expansion Of The Arthritis Monoclonal Antibodies Market?
The rising approvals for personalized medicines are anticipated to propel the arthritis monoclonal antibody market moving forward. Personalized medicines are defined as therapeutic products or treatments customized for the individual patient, developed based on a patient’s genetic, biomarker, phenotypic, or psychosocial characteristics that can predict their response to a treatment. Monoclonal antibodies (mABs) represent the latest generation of drugs that align with the personalized medicine paradigm and offer the potential to enhance patient outcomes and healthcare efficiency. For instance, in February 2024, a report from the Personalized Medicine Coalition, a US-based non-profit organization promoting the adoption of personalized medicine, highlighted the importance of 26 newly approved personalized treatments, 19 expanded indications for existing personalized medicines, and 17 notable new or expanded indications for 12 diagnostic testing products. Consequently, the increasing approvals for personalized medicines are a driving force for the arthritis monoclonal antibody market.
What Are The Key Segment Divisions In The Arthritis Monoclonal Antibodies Market Segment Structure?
The arthritis monoclonal antibodies market covered in this report is segmented –
1) By Drug: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima
2) By Application: Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia, Other Applications
3) By End-Use: Hospitals, Research Institutes, Other End-Users
Which Trends Are Shaping The Arthritis Monoclonal Antibodies Market?
Leading companies in the arthritis monoclonal antibody market are introducing new biosimilar versions, such as Hulio, to make treatment more affordable. Hulio is a biosimilar equivalent of AbbVie’s highly successful rheumatoid arthritis medication, Humira. For example, in July 2023, Biocon Biologics, an India-based subsidiary of Biocon Limited dedicated to biosimilar therapy development, launched Hulio (adalimumab-fkjp), a biosimilar counterpart to Humira. This monoclonal antibody, prescribed for conditions like rheumatoid arthritis and psoriatic arthritis, is priced 5% lower than Humira, which is presently listed at $6,922 per carton.
Which Organizations Are Engaged In The Arthritis Monoclonal Antibodies Market?
Major companies operating in the arthritis monoclonal antibodies market are Johnson & Johnson, Hoffmann-La Roche Ltd., Novartis AG, Pfizer Inc., AbbVie Inc., Amgen Inc., Genentech Inc., GlaxoSmithKline plc., AstraZeneca plc, Bristol Myers Squibb, Eli Lilly and Company, Thermo Fisher Scientific Inc., Sanofi SA, Daiichi Sankyo Company Ltd., Seattle Genetics, Teva Pharmaceutical Industries Ltd., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Corp., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Boehringer Ingelheim International GmbH, Celltrion Inc., HanAll Biopharma Co. Ltd., Merck & Co. Inc., Mitsubishi Tanabe Pharma Corporation, Regeneron Pharmaceuticals Inc., Samsung Bioepis Co. Ltd.
Get The Full Arthritis Monoclonal Antibodies Market Report:
Which Geographic Region Dominates The Arthritis Monoclonal Antibodies Market?
North America was the largest region in the arthritis monoclonal antibodies market in 2025. The regions covered in the arthritis monoclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Arthritis Monoclonal Antibodies Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Arthritis Monoclonal Antibodies Market 2026, By The Business Research Company
Musculoskeletal Disorder Drugs Market Report 2026
Microbiome Therapeutics Market Report 2026
https://www.thebusinessresearchcompany.com/report/microbiome-therapeutics-global-market-report
Orthobiologics Devices And Equipment Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model